valanafusp alfa (AGT-181)
/ JCR Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 21, 2023
Safety and Dose Ranging Study of Insulin Receptor MAb-IDUA Fusion Protein in Patients With MPS I
(clinicaltrials.gov)
- P1 | N=3 | Completed | Sponsor: ArmaGen, Inc | Unknown status ➔ Completed
Trial completion • Hurler Syndrome
1 to 1
Of
1
Go to page
1